SR 41476
Latest Information Update: 21 Mar 1995
At a glance
- Originator Sanofi-Synthelabo
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 21 Mar 1995 No-Development-Reported for HIV infections treatment in France (Unknown route)
- 29 Nov 1994 Preclinical development for HIV-1 infections in France (Unknown route)